1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: The following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted by our directors and executive officers during the quarter ended March 31, 2024.
−Removed: No trading arrangements were terminated by our directors and executive officers during the quarter ended March 31, 2024.
−Removed: Trading Arrangement
−Removed: Name and Position Action Date Rule 10b5-1* Non-Rule
−Removed: 10b5-1** Total Number of
−Removed: Shares to be Sold Expiration
−Removed: Principal Accounting Officer
−Removed: Adopt 3/5/2024 x To Be Determined (1)
−Removed: Kristen Williams
−Removed: Chief Administrative Officer and Secretary
−Removed: Adopt 3/8/2024 x To Be Determined (1)
−Removed: Jonathan Slonin
−Removed: Chief Medical Officer
−Removed: Adopt 3/8/2024 x To Be Determined (1)
−Removed: Paul Hastings
−Removed: Adopt 3/12/2024 x 1,775 12/31/2024
−Removed: Daryl Gaugler
−Removed: Chief Operating Officer
−Removed: Adopt 3/12/2024 x 2,500 3/7/2025
−Removed: * Intended to satisfy the affirmative defense of Rule 10b5-1(c).
−Removed: ** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).
−Removed: (1) The aggregate number of shares to be sold pursuant to each trading arrangement listed above is dependent on the amount of tax withholding required upon the vesting of restricted stock units, and, therefore, is indeterminable at this time.
+Added: During the quarter ended June 30, 2024, no director or executive officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Pacira BioSciences, Inc.
2 unchanged sentences
Exhibit Number Description
−Removed: Executive Employment Agreement, dated May 4, 2020, between the Registrant and Jonathan Slonin.(1) ***
+Added: Indenture, dated as of May 14, 2024, by and between the Registrant and Computershare Corporate Trust, National Association.(1)
+Added: Form of Global 2.125% Convertible Senior Notes due 2029 (included in Exhibit 4.1).(1)
+Added: First Amendment, dated as of May 8, 2024, to Credit Agreement, dated as of March 31, 2023, by and among Pacira BioSciences, Inc., the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.(2)
+Added: Form of Capped Call Transaction Confirmation.(1)
+Added: Fifth Amendment to Consulting Agreement, dated June 12, 2024, between the Registrant and Gary Pace.***
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
3 unchanged sentences
101 The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc.
−Removed: for the quarter ended March 31, 2024, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: for the quarter ended June 30, 2024, formatted in iXBRL (Inline eXtensible Business Reporting Language):
(i) the Condensed Consolidated Balance Sheets;
(ii) the Condensed Consolidated Statements of Operations;
−Removed: (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss);
+Added: (iii) the Condensed Consolidated Statements of Comprehensive Income;
(iv) the Condensed Consolidated Statements of Stockholders’ Equity;
5 unchanged sentences
*** Denotes management contract or compensatory plan or arrangement.
−Removed: (1) Incorporated by reference to the Company’s Quarterly Report on Form 10-Q, filed on May 4, 2022.
+Added: + Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
+Added: The Company hereby undertakes to supplementally furnish copies of any omitted schedules and exhibits to the Securities and Exchange Commission upon request.
+Added: (1) Incorporated by reference to the Company’s Current Report on Form 8-K, filed on May 14, 2024.
+Added: (2) Incorporated by reference to the Company’s Current Report on Form 8-K, filed on May 8, 2024.
Pacira BioSciences, Inc.
2 unchanged sentences
PACIRA BIOSCIENCES, INC.
−Removed: May 7, 2024 By:
+Added: July 30, 2024 By:
Chief Executive Officer and Director
(Principal Executive Officer)
−Removed: May 7, 2024 By:
+Added: July 30, 2024 By:
/s/ CHARLES A.
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.